Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia

Leukemia. 2007 Mar;21(3):556-60. doi: 10.1038/sj.leu.2404537. Epub 2007 Feb 1.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Busulfan / administration & dosage
  • Busulfan / adverse effects
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Female
  • Hematopoietic Stem Cell Transplantation / mortality
  • Hematopoietic Stem Cell Transplantation / statistics & numerical data*
  • Humans
  • Infant
  • Leukemia, Myelomonocytic, Acute / drug therapy
  • Leukemia, Myelomonocytic, Acute / surgery*
  • Leukemia, Myelomonocytic, Chronic
  • Male
  • Postoperative Complications / mortality
  • Recurrence
  • Remission Induction
  • Reoperation
  • Salvage Therapy*
  • Splenectomy
  • Transplantation Conditioning / adverse effects
  • Transplantation Conditioning / methods
  • Transplantation, Homologous / statistics & numerical data*
  • Treatment Outcome
  • Whole-Body Irradiation / adverse effects

Substances

  • Busulfan